3Jordan RM,Mintz RD.Fatal reaction to gadopentetate dime-glumine[J].AJR,1995,164(3):743-744.
4Abujudeh HH,Kosaraju VK,Kaewlai R.Acute adverse reactions to gadopentetate dimeglumine and gadobenate dimeglumine:experience with 32659 injections[J].AJR,2010,194(2):430-434.
5Nelson KL,Gifford LM,Lauber-Huber C,et al.Clinical safety of gadopentetate dimeglumine[J].Radiology,1995,196(2):439-443.
6Ridder F,Maeseneer M,Stadnik T,et al.Severe adverse reactions with contrast agents for magnetic resonance:clinical experience in 30,000 MR examinations[J].JBR-BTR,2001,84(4):150-152.
7Kirchin MA,Pirovano G,Venetianer C,et al.Safety assessment of gadobenate dimeglumine (MultiHance):extended clinical experience from phase Ⅰstudies to post-marketing surveillance[J].JMRI,2001,14(3):281-294.
8Herborn CU,Jager-Booth I,Lodemann KP,et al.Multicenter analysis of tolerance and clinical safety of the extracellular MR contrast agent gadobenate dimeglumine (MultiHance)[J].Rofo,2009,181(7):652-657.
9Petersein J,Spinazzi A,Giovagnoni A,et al.Focal liver lesions:evaluation of the efficacy of gadobenate dimeglumine in MR imaging a multicenter phase Ⅲ clinical study[J].Radiology,2000,215(3):727-736.
10Marckmann P,Skov L,Rossen K,et al.Nephrogenic systemic fibrosis:suspected causative role of gadodiamide used for contrast-enhanced magnetic resonance imaging[J].JAm Soc Nephrol,2006,17(9):2359-2362.
